Predictors of new-onset diabetes mellitus in hypertensive patients: the VALUE trial

被引:0
作者
T A Aksnes
S E Kjeldsen
M Rostrup
Ö Störset
T A Hua
S Julius
机构
[1] Ullevaal University Hospital,Department of Cardiology
[2] Ullevaal University Hospital,Department of Acute Medicine
[3] Akershus University Hospital,Department of Internal Medicine
[4] Novartis Pharma,Department of Internal Medicine, Division of Cardiovascular Medicine
[5] University of Michigan,undefined
来源
Journal of Human Hypertension | 2008年 / 22卷
关键词
blood pressure; cardiovascular risk; diabetes mellitus; glucose; overweight;
D O I
暂无
中图分类号
学科分类号
摘要
Diabetes mellitus often develops in patients with hypertension. We investigated predictors of diabetes mellitus development in hypertensives at risk of developing the disease in the VALUE trial population. Among the 9995 non-diabetic hypertensive patients at baseline, 1298 patients developed diabetes mellitus during the average follow-up of 4.2 years. New-onset diabetes mellitus was defined from adverse event reports, information about new antidiabetic medication and/or a fasting glucose ⩾7.0 mmol l−1 at the end of trial. Twenty-five potential baseline predictors of new-onset diabetes mellitus were analysed by univariate logistic regression and 14 of 25 predictors were found to be statistically significant with a P-value <0.05. The predictors were in order of decreasing significance; glucose, body mass index (BMI), age, uric acid, non-Caucasian race, haemoglobin, heart rate, randomized study treatment, history of coronary heart disease (CHD), gender, total cholesterol, proteinuria, potassium and creatinine. Multivariate stepwise logistic regression analyses were used and potential baseline predictors of new-onset diabetes mellitus were considered significant by four different models (P-value <0.001). The final multivariate model selected included all patients, but not treatment group as a potential predictor, and the six significant predictors identified from this model were glucose, BMI, non-Caucasian race, age, heart rate and history of CHD. In conclusion, glucose and BMI were the most important predictors of new-onset diabetes mellitus in hypertensive patients at high cardiovascular risk, and easily accessible clinical characteristics strongly predict patients at risk of developing diabetes mellitus.
引用
收藏
页码:520 / 527
页数:7
相关论文
共 132 条
[1]  
Howard BV(2002)Prevention Conference VI: Diabetes and Cardiovascular disease: Writing Group I: epidemiology Circulation 105 e132-e137
[2]  
Rodriguez BL(2002)Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study J Hypertens 20 1879-1886
[3]  
Bennett PH(2004)Development of diabetes is retarded by ACE inhibition in hypertensive patients—a subanalysis of the Captopril Prevention Project (CAPPP) J Hypertens 22 645-652
[4]  
Harris MI(1998)The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design Blood Press 7 176-183
[5]  
Hamman R(2001)Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term Use Evaluation Blood Press 10 83-91
[6]  
Kuller LH(2004)Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial Lancet 363 2022-2031
[7]  
Lindholm LH(1985)Diabetes mellitus. Report of a WHO Study Group World Health Organ Tech Rep Ser 727 1-113
[8]  
Ibsen H(1998)Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation Diabet Med 15 539-553
[9]  
Borch-Johnsen K(2004)Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial Lancet 363 2049-2051
[10]  
Olsen MH(2003)Lowering the criterion for impaired fasting glucose is in order Diabetes Care 26 3331-3332